Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Overview of attention for article published in Biomarker Research, March 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#37 of 320)
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 287 Dimensions

Readers on

mendeley: 319 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Epizyme's tazemetostat shows positive action in mid-stage FL study

Seeking Alpha, 07 Dec 2019

Results from an open-label Phase 2 clinical trial evaluating Epizyme's (NASDAQ: EPZM ) tazemetostat in follicular lymphoma (FL…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.